Oric Pharmaceuticals
ORIC
ORIC
92 hedge funds and large institutions have $470M invested in Oric Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 36 increasing their positions, 20 reducing their positions, and 17 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more capital invested
Capital invested by funds: $ → $
more first-time investments, than exits
New positions opened: | Existing positions closed:
17% more funds holding in top 10
Funds holding in top 10: 6 → 7 (+1)
5.59% more ownership
Funds ownership: 88.12% → 93.71% (+5.6%)
2% more funds holding
Funds holding: 90 → 92 (+2)
Holders
92
Holding in Top 10
7
Calls
$4M
Puts
$1.84M
Top Buyers
| 1 | +$35.6M | |
| 2 | +$7.7M | |
| 3 | +$6.07M | |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$5.58M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$4.79M |
Top Sellers
| 1 | -$9.21M | |
| 2 | -$7.04M | |
| 3 | -$5.86M | |
| 4 |
O
OrbiMed
New York
|
-$3.41M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$3.09M |